Global Regenerative Medicine Market Size study, by Product, by Application, by End User, and Regional Forecasts 2022-2032

Description

Global Regenerative Medicine Market is valued at approximately USD 34.56 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 32.4% over the forecast period 2024-2032. Regenerative medicine is an innovative field aiming to repair, replace, or regenerate damaged tissues or organs using cells, tissues, or genetic material. This technology offers the potential to treat and cure various chronic, intractable, and terminal diseases such as cancer, Parkinson's disease, Alzheimer's, diabetes, renal diseases, cardiovascular diseases, and many others. The rapid advancements in gene therapy, including the first successful in-vivo CRISPR therapy in 2021, have significantly propelled market growth. Additionally, the rising prevalence of chronic genetic disorders and increased healthcare expenditure across developed and developing nations are driving the expansion of the regenerative medicine industry.

The Global Regenerative Medicine Market is witnessing strong growth, bolstered by strategic investments and partnerships within the sector. For instance, government support for R&D is playing a pivotal role in market growth. In 2022, Washington University received a grant from the National Heart Lung and Blood Institute (NHLBI) to investigate regenerative therapies for diabetic vascular and skeletal muscle repair. Collaborations between tech and biotech firms are further accelerating advancements in the sector, as seen in the partnership between Wipro and Pandorum Technologies in 2022, which aims to integrate artificial intelligence into drug development to maximize clinical outcomes and reduce time to market.

Major players operating in the regenerative medicine market are focusing on R&D to maintain their competitive edge and to launch innovative therapies. The market is characterized by strong investment in clinical trials aimed at expanding the range of available treatments. For example, CRISPR Therapeutics' ongoing trials in gene editing therapies for cancer and rare diseases are expected to lead to new product launches, driving growth during the forecast period. However, the high cost of regenerative treatments and the lack of comprehensive reimbursement policies are key challenges that may restrain market expansion, particularly for patients requiring out-of-pocket payments for experimental therapies.

The key regions considered for the Global Regenerative Medicine Market study include Asia Pacific, North America, Europe, Latin America, Middle East & Africa, and Rest of the World. North America is a dominating region in the Global Regenerative Medicine Market in terms of revenue. The market growth in the region is being attributed to factors including advanced healthcare infrastructure, significant investments in research and development, and a high prevalence of chronic diseases. The presence of major industry players and favorable regulatory policies also contribute to the region's leading position. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising healthcare expenditure, increasing awareness of regenerative therapies, and a growing patient population with unmet medical needs are propelling rapid market growth in this region. Expanding government initiatives and collaborations in biotechnology further accelerate its growth.

Major market player included in this report are:

Integra LifeSciences Corporation (U.S.)
Bristol-Myers Squibb Company (U.S.)
Novartis AG (Switzerland)
Janssen Global Services, LLC (Belgium)
CRISPR Therapeutics (Switzerland)
Stryker (U.S.)
Smith & Nephew (U.K.)
Allergan Aesthetics (AbbVie Inc.) (U.S.)
American CryoStem Corporation (U.S.)
Tegoscience (South Korea)
MIMEDX (U.S.)
Tissue Regenix (U.K.)
Kite (Gilead Sciences, Inc.) (U.S.)
AlloSource (U.S.)
bluebird bio, Inc. (U.S.)

The detailed segments and sub-segment of the market are explained below:

By Product

Cell Therapy
Gene Therapy
Tissue Engineering
Platelet Rich Plasma

By Application

Orthopedics
Wound Care
Oncology
Rare Diseases
Others

By End User

Hospitals
Clinics
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approaches.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Regenerative Medicine Market Executive Summary

1.1. Global Regenerative Medicine Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Product
- 1.3.2. By Application
- 1.3.3. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Regenerative Medicine Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Regenerative Medicine Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing R&D Investments
- 3.1.2. Technological Advancements in Gene Therapy
- 3.1.3. Growing Government Support
3.2. Market Challenges
- 3.2.1. High Treatment Costs
- 3.2.2. Inadequate Reimbursement Policies
3.3. Market Opportunities
- 3.3.1. Expansion in Asia Pacific
- 3.3.2. Increasing Product Approvals

Chapter 4. Global Regenerative Medicine Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Regenerative Medicine Market Size & Forecasts by Product (2022-2032)

5.1. Segment Dashboard
5.2. Global Regenerative Medicine Market: By Product Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Cell Therapy
- 5.2.2. Gene Therapy
- 5.2.3. Tissue Engineering
- 5.2.4. Platelet Rich Plasma

Chapter 6. Global Regenerative Medicine Market Size & Forecasts by Application (2022-2032)

6.1. Segment Dashboard
6.2. Global Regenerative Medicine Market: By Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Orthopedics
- 6.2.2. Wound Care
- 6.2.3. Oncology
- 6.2.4. Rare Diseases
- 6.2.5. Others

Chapter 7. Global Regenerative Medicine Market Size & Forecasts by End User (2022-2032)

7.1. Segment Dashboard
7.2. Global Regenerative Medicine Market: By End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospitals
- 7.2.2. Clinics
- 7.2.3. Others

Chapter 8. Global Regenerative Medicine Market Size & Forecasts by Region (2022-2032)

8.1. North America Regenerative Medicine Market
- 8.1.1. U.S. Market Size & Forecast
  - 8.1.1.1. Product breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Application breakdown size & forecasts, 2022-2032
  - 8.1.1.3. End User breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Market Size & Forecast
8.2. Europe Regenerative Medicine Market
- 8.2.1. UK Market Size & Forecast
- 8.2.2. Germany Market Size & Forecast
- 8.2.3. France Market Size & Forecast
- 8.2.4. Spain Market Size & Forecast
- 8.2.5. Italy Market Size & Forecast
- 8.2.6. Rest of Europe Market Size & Forecast
8.3. Asia Pacific Regenerative Medicine Market
- 8.3.1. China Market Size & Forecast
- 8.3.2. India Market Size & Forecast
- 8.3.3. Japan Market Size & Forecast
- 8.3.4. Australia Market Size & Forecast
- 8.3.5. South Korea Market Size & Forecast
- 8.3.6. Rest of Asia Pacific Market Size & Forecast
8.4. Latin America Regenerative Medicine Market
- 8.4.1. Brazil Market Size & Forecast
- 8.4.2. Mexico Market Size & Forecast
- 8.4.3. Rest of Latin America Market Size & Forecast
8.5. Middle East & Africa Regenerative Medicine Market
- 8.5.1. Saudi Arabia Market Size & Forecast
- 8.5.2. South Africa Market Size & Forecast
- 8.5.3. Rest of Middle East & Africa Market Size & Forecast

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Integra LifeSciences Corporation
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Bristol-Myers Squibb Company
- 9.3.3. Novartis AG
- 9.3.4. Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
- 9.3.5. CRISPR Therapeutics
- 9.3.6. Stryker
- 9.3.7. Smith & Nephew
- 9.3.8. Allergan Aesthetics (AbbVie Inc.)
- 9.3.9. American CryoStem Corporation
- 9.3.10. Tegoscience
- 9.3.11. MIMEDX (U.S.)
- 9.3.12. Tissue Regenix (U.K.)
- 9.3.13. Kite (Gilead Sciences, Inc.) (U.S.)
- 9.3.14. AlloSource (U.S.)
- 9.3.15. bluebird bio, Inc. (U.S.)

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes